

March 26, 2026

Dear All,

Company Name: Delta-Fly Pharma, Inc.
(Code number : 4598 TSE Growth Market)
Inquiries: Kenzo Iizuka, Senior Vice President, R&D
(Contact: <https://www.delta-flypharma.co.jp/en/contactentrance/>)

Notice Regarding Partial Corrections and Inquiries Regarding the " Announcement Regarding the Data Monitoring Committee Decision on the Phase 1/2 Study of DFP-10917 combination with Venetoclax in Relapsed or Refractory AML"

This notice concerns partial corrections and inquiries regarding the " Announcement Regarding the Data Monitoring Committee Decision on the Phase 1/2 Study of DFP-10917 combination with Venetoclax in Relapsed or Refractory AML" which was published on March 25, 2026.

1. [Correction Details]

<Before Correction>

....

The DMC reviewed the summary of reported responses and noted the overall response rate, 50% (1 patient of CR and 2 patients of MLFS) in the Phase 1 safety cohort, and 53% (3 patients of CRi and 3 patients of MLFS) in the Phase 2 expansion cohort. Accordingly, 4 patients transitioned to stem cell transplantation.

....

< Correction >

....

The DMC reviewed the summary of reported responses and noted the overall response rate, 50% (1 patient of CR and 2 patients of MLFS) in the Phase 1 safety cohort, and 53% (3 patients of CRi , 3 patients of MLFS and 3 partial remissions (PR)) in the Phase 2 expansion cohort. Accordingly, 4 patients transitioned to stem cell transplantation.

....

* Underlined section indicates correction

2. [Question]

Regarding the " Announcement Regarding the Data Monitoring Committee Decision on the Phase 1/2 Study of DFP-10917 combination with Venetoclax in Relapsed or Refractory AML" announced yesterday (March 25th), we received inquiries regarding the statement that " the overall response rate, 50% (1 patient of CR and 2 patients of MLFS) in the Phase 1 safety cohort*¹, and 53% (3 patients of CRi and 3 patients of MLFS) in the Phase 2 expansion cohort*²." We received inquiries about whether there is a discrepancy in the overall response rate or error in description.

<Answer>

Regarding your question, the calculation basis, including the correction, is described below.

*¹ The Phase 1 safety cohort mentioned includes 3 patients out of 6 registered patients:
1 patient of CR and 2 patients of MLFS.

$$\text{ORR} = 3 \text{ patients} / 6 \text{ patients} = 50\%$$

*² The Phase 2 expanded cohort mentioned includes 9 patients out of 17 registered patients: 3 patients of CRi, 3 patients of MLFS, and 3 patients of PR.

$$\text{ORR} = 9 \text{ patients} / 17 \text{ patients} = 53\%$$

END